Plain-English translation of NCT07455955 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a simple genetic test can help doctors pick the best nausea-prevention medication for women starting chemotherapy for breast cancer. Some patients will receive a genetic analysis to guide their anti-nausea treatment, while others will receive standard nausea prevention. The goal is to see if personalized medication choices based on your genes help you feel better during treatment.
Nausea and vomiting are common and distressing side effects of chemotherapy, and different people respond differently to the same anti-nausea medications. This trial exists to see whether genetic testing can help doctors predict which medication will work best for each individual patient, potentially reducing suffering during cancer treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive genetic testing or standard care. If you receive genetic testing, doctors will analyze your genes to determine which anti-nausea medication is best for you, and you may receive standard medication or a medication called Olanzapine depending on your results. Either way, you will take anti-nausea medications during your first cycle of chemotherapy and complete questionnaires and a diary to track how you feel.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Hong Kong